Read the Latest News

Hyperreactive Brain Network May Be Cause of Chronic Pain in Fibromyalgia, Study Suggests

Fibromyalgia is one of the overlapping pain conditions with TMD. This article appeared in Fibromyalgia News Today on January 15, 2018. A new study suggests a hyperreactive brain network may be the underlying cause of chronic pain in fibromyalgia.

Dry Eye Linked to Chronic Overlapping Pain in Veteran Population

There may be a correlation between dry eye and chronic pain in the US military veteran population as is evident by a recent study. Ocular pain was most strongly associated with headaches, tension headaches, migraines, temporomandibular joint disorders, pelvic pain, central pain syndrome, and fibromyalgia in the veteran patient population.

Patients in Los Angeles or New York City Needed for Clinical Study - Comparative Study of Women Considering or Currently Receiving Botox© Injections for TMJ Pain

Are you a woman with "TMJ" pain in facial muscles, who has either: a. recently had Botox© injections for your pain or b. not had Botox© for your pain but has thought about such treatment? If either is true for you, you may qualify for an observational research study centrally administered by the NYU College of Dentistry. It is funded by the National Institutes of Health (NIH). The purpose of this study is to understand potential health risks that may be caused by treating "TMJ pain" with Botox© injections.

Why Head and Face Pain Cause More Suffering

Hate headaches? The distress you feel is not all in your -- well, head. People consistently rate pain of the head, face, eyeballs, ears and teeth as more disruptive, and more emotionally draining, than pain elsewhere in the body.

Migraine and Coronary Artery Disease: A Genetic Connection

There has long been as association between migraine headaches and vascular (blood vessel) dysfunction of some kind, underscored by epidemiological studies and other research. New evidence for a genetic connection now comes from the analysis of several large data sets of each condition based on Genome Wide Association Studies (GWAS).

Partnering to Improve Chronic Pain Care

  • Oct 5, 2017

Cutting Edge Science Meeting to End Opioid Crisis - Understanding the Neurobiological Mechanisms of Pain

Partnering to Improve Chronic Pain Care

The National Institutes of Health (NIH) held three meetings this summer with the goal of developing the first public-private partnership (PPP) to develop safe and effective treatments for chronic pain, as well as new treatments for opioid addiction and overdose. The proposed partnership would be a joint effort of the NIH, the U.S. Food and Drug Administration (FDA) and the pharmaceutical and medical device industry. Christin Veasley, Director of the Chronic Pain Research Alliance, an initiative of TMJA, was invited to participate in the third meeting focused on the neurobiology of pain. The meeting was hosted by NIH Director, Dr. Frances Collins and the NIH principal Deputy Director, Dr. Lawrence Tabak. Other attendees included several NIH Institute Directors, clinical and basic scientists in pain research and representatives of pharmaceutical and device companies.

Christin was asked to address chronic pain research from her perspective as a chronic pain patient and patient advocate. She noted that pain receives limited research investment, is frequently dismissed by health care professionals, and is not regarded as a major public health problem, despite being the most prevalent, costly and disabling condition in the U.S. Further, the admission of pain remains a source of stigma for patients and is regarded by society as a sign of weakness.

Christin highlighted issues with the current treatment system, namely the shortage of pain specialists, the dearth of education and training in pain management for primary care physicians and the lack of quality evidence of various therapies. This leads to trial-and-error-based clinical decision making. To improve the care of pain patients, better measures of pain are needed, she stated, along with preclinical models and clinical trials that account for the complexity and individuality of responses to the chronic pain experience. These measures should include an assessment of comorbidities, such as sleep and mood disorders, the loss of functional abilities and health-related quality of life. She emphasized that a precision medicine approach to clarify how genetics, environmental factors and lifestyle interact in an individual pain patient's experience can lead to tailored treatments that can more effectively manage pain. Christin concluded that pain research will greatly benefit from the participation of stakeholders from across the research and clinical translation spectrum, including patients, clinicians and payers.  (Click to view the PowerPoint presentation)

The meeting summary, along with those of the earlier two meetings, can be viewed on the NIH's website: https://www.nih.gov/opioid-crisis. Dr. Collins has since met with leaders of pharmaceutical and medical device companies to discuss potential collaborations with the NIH and FDA on some of the projects proposed at the meetings.

Christin is now serving on the planning committee and will be speaking at a follow-up meeting, commissioned by the NIH, to be held October 11-12, 2017 at the National Academies of Sciences, Engineering and Medicine. Additional information on the meeting can be viewed online:

http://www.nationalacademies.org/hmd/Activities/Research/NeuroForum/2017-OCT-11.aspx.

We invite you to read a recent blog post in which Christin Veasley shares some of the lessons she's learned from 30 years of living with chronic pain. 

Overlapping Conditions

Comments:

Login or Register to add Comment